MARKET

ZOM

ZOM

Zomedica Corp
AMEX

Real-time Quotes | Nasdaq Last Sale

0.3403
+0.0103
+3.12%
After Hours: 0.3395 -0.0008 -0.24% 16:37 12/06 EST
OPEN
0.3402
PREV CLOSE
0.3300
HIGH
0.3500
LOW
0.3230
VOLUME
19.58M
TURNOVER
--
52 WEEK HIGH
2.910
52 WEEK LOW
0.1502
MARKET CAP
333.46M
P/E (TTM)
-14.7957
1D
5D
1M
3M
1Y
5Y
Zomedica posts widening Q3 net loss as SG&A expenses more than doubles
Zomedica (NYSE:ZOM) has lost ~5.5% in the post-market after the company reported Q3 2021 financials that indicated rising net loss amid a surge in selling, general and administrative expenses (SG&A) for the quarter.
Seekingalpha · 11/12 22:39
Zomedica reports Q3 results
Zomedica (NYSE:ZOM): Q3 GAAP EPS of -$0.01. Revenue of $22.51K Shares -0.93%. Press Release Zomedica had cash and cash equivalents of approximately $271.4 million as of September 30, 2021, compared
Seekingalpha · 11/12 21:17
Zomedica Announces Third Quarter 2021 Financial Results
ANN ARBOR, MI / ACCESSWIRE / November 12, 2021 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or "Company"), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today reported consolidated financial results...
AccessWire · 11/12 21:10
MSCI adds ZOM, CLOV, 110 others to US Micro Cap Index, MNKD, SAVA to be deleted
MSCI will be including total 112 companies  including  Zomedica (NYSE:ZOM), Clovis Oncology (NASDAQ:CLOV), 22nd Century (NASDAQ:XXII), Omeros (NASDAQ:OMER) and Verastem (NASDAQ:VSTM) in its MSCI US Micro Cap Index as a part of Semi-Annual
Seekingalpha · 11/12 19:27
Zomedica Q3 Net Loss Stays Steady Compared With Year-Ago Quarter
MT Newswires · 11/12 16:31
Zomedica Management Finally Delivers Some Good News
Investor Place · 10/21 19:41
SPAR Group Elects Mr. Sean M. Whelan and Mr. Michael Wager to its Board of Directors
The SPAR Group, Inc. (NASDAQ: SGRP) ("SPAR Group") board of directors (the Board") has elected Sean M. Whelan and Michael Wager to the Board, effective October 14, 2021.
GlobeNewswire · 10/21 12:00
New CEO and Acquisition Could Breathe New Life Into Zomedica
Investor Place · 10/11 16:29
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ZOM. Analyze the recent business situations of Zomedica Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ZOM stock price target is 1.200 with a high estimate of 1.200 and a low estimate of 1.200.
High1.200
Average1.200
Low1.200
Current 0.3378
EPS
Actual
Estimate
-0.01-0.01-0.00-0.00
  • 0
Q3 2020
  • 0
Q4 2020
    00
Q1 2021
    0
Q2 2021
Q3 2021
Institutional Holdings
Institutions: 30
Institutional Holdings: 14.30M
% Owned: 1.46%
Shares Outstanding: 979.89M
TypeInstitutionsShares
Increased
10
618.54K
New
6
747.38K
Decreased
7
136.68K
Sold Out
15
2.83M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.95%
Pharmaceuticals & Medical Research
-0.64%
Key Executives
Non-Executive Chairman/Independent Director
Jeffrey Rowe
Chief Executive Officer
Larry Heaton
Chief Financial Officer/Secretary
Ann Cotter
Chief Operating Officer
Stephanie Morley
Director
Robert Cohen
Director
Sean Whelan
Independent Director
Christopher MacLeod
Independent Director
Johnny Powers
Independent Director
Rodney Williams
No Data
About ZOM
Zomedica Corp. is a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians. The Company is developing point-of-care diagnostic platform, which is based on miniaturized laser-based Raman spectroscopy technology and is designed to detect pathogens in companion animals. It offers TRUFORMA is a diagnostic biosensor platform and the first five assays for the detection of thyroid disorders in dogs and cats and adrenal disorders in dogs. The TRUFORMA platform uses bulk acoustic wave (BAW) technology to provide a non-optical and fluorescence free detection system for use at the point-of-care. The TRUFORMA also offers complete control over the testing process from start to finish, with sensitive and specific immunoassays that allow veterinarians to make clinical decisions.

Webull offers kinds of Zomedica Corp stock information, including AMEX:ZOM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZOM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZOM stock methods without spending real money on the virtual paper trading platform.